drugset

drugset / Trial / NCT00200902

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902 ↗

Phase 4 Completed 88 enrolled University of California, Los Angeles Eli Lilly and Company · collab National Center for Complementary and Integrative Health (NCCIH) · collab Wyeth is now a wholly owned subsidiary of Pfizer · collab

RandomizedFactorialTriple-blindTreatment

Summary

This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.

Timeline

Start: 2005-08
Primary completion: 2009-06
Completion: 2009-06

Publications

Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014 Dec;205(6):443-9. doi: 10.1192/bjp.bp.113.140343. Epub 2014 Sep 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Duloxetine	Small molecule	90 mg	—
Comparator	Escitalopram	Small molecule	30 mg	—
Comparator	Venlafaxine	Small molecule	225 mg	—

Indications